Maurizio Provenzano

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. pmc Frequency of MART-1/MelanA and gp100/PMel17-specific T cells in tumor metastases and cultured tumor-infiltrating lymphocytes
    Simone Seiter
    Department of Transfusion Medicine, Center for Cancer Research, National Cancer Institute, Building 10, Room 2B42, 9000 Rockville Pike, Bethesda, MD 20892, USA
    J Immunother 25:252-63. 2002
  2. ncbi request reprint The matrix protein pp65(341-350): a peptide that induces ex vivo stimulation and in vitro expansion of CMV-specific CD8+ T cells in subjects bearing either HLA-A*2402 or A*0101 allele
    Maurizio Provenzano
    Department of Transfusion Medicine, Warren G Magnuson Clinical Center, National Institutes of Health, Bethesda, Maryland 20892, USA
    Transfusion 43:1567-74. 2003
  3. pmc Ex vivo screening for immunodominant viral epitopes by quantitative real time polymerase chain reaction (qRT-PCR)
    Maurizio Provenzano
    Molecular Immunology Section, Department of Transfusion Medicine, Clinical Center, NIH, Bethesda, USA
    J Transl Med 1:12. 2003
  4. ncbi request reprint Identification of immune dominant cytomegalovirus epitopes using quantitative real-time polymerase chain reactions to measure interferon-gamma production by peptide-stimulated peripheral blood mononuclear cells
    Maurizio Provenzano
    Department of Transfusion Medicine, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Immunother 25:342-51. 2002
  5. pmc Functional heterogeneity of vaccine-induced CD8(+) T cells
    Vladia Monsurro
    Immunogenetics Section, Department of Transfusion Medicine, Clinical Center, and Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 168:5933-42. 2002
  6. ncbi request reprint Proteasomal cleavage does not determine immunogenicity of gp100-derived peptides gp100 209-217 and gp100 209-217T210M
    Dirk Nagorsen
    Immunogenetics Section, Department of Transfusion Medicine, NIH Clinical Center, 10 Center Drive, Bethesda, MD 20892 1502, USA
    Cancer Immunol Immunother 53:817-24. 2004
  7. ncbi request reprint Gene expression signatures of interleukin-2 in vivo and in vitro and their relation to anticancer therapy
    Ping Jin
    Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA
    Crit Rev Immunol 27:437-48. 2007
  8. pmc The antileukemia effect of HLA-matched NK and NK-T cells in chronic myelogenous leukemia involves NKG2D-target-cell interactions
    Giuseppe Sconocchia
    Stem Cell Allotransplantation Section, Hematology Branch, National Heart Lung and Blood Institute, Department of Transfusion Medicine, Clinical Center, National Institutes of Health NIH, Bethesda, MD 20892, USA
    Blood 106:3666-72. 2005
  9. doi request reprint Pilot study of mutant ras peptide-based vaccine as an adjuvant treatment in pancreatic and colorectal cancers
    Antoun Toubaji
    Cancer Vaccine Section, Vaccine Branch, NCI, NIH, NNMC, Bldg 8, Room 5101, 8901 Wisconsin Ave, Bethesda, MD 20889, USA
    Cancer Immunol Immunother 57:1413-20. 2008
  10. ncbi request reprint Identification of HLA-A33-restricted CMV pp65 epitopes as common targets for CD8(+) CMV-specific cytotoxic T lymphocytes
    Jong Baeck Lim
    Department of Laboratory Medicine, Yonsei University College of Medicine, Seoul, Korea
    Exp Hematol 34:296-307. 2006

Collaborators

Detail Information

Publications13

  1. pmc Frequency of MART-1/MelanA and gp100/PMel17-specific T cells in tumor metastases and cultured tumor-infiltrating lymphocytes
    Simone Seiter
    Department of Transfusion Medicine, Center for Cancer Research, National Cancer Institute, Building 10, Room 2B42, 9000 Rockville Pike, Bethesda, MD 20892, USA
    J Immunother 25:252-63. 2002
    ..These data provide direct enumeration of MART-1/MelanA and gp100/pMel17 reactivity ex vivo and in vitro in the context of HLA-A*0201...
  2. ncbi request reprint The matrix protein pp65(341-350): a peptide that induces ex vivo stimulation and in vitro expansion of CMV-specific CD8+ T cells in subjects bearing either HLA-A*2402 or A*0101 allele
    Maurizio Provenzano
    Department of Transfusion Medicine, Warren G Magnuson Clinical Center, National Institutes of Health, Bethesda, Maryland 20892, USA
    Transfusion 43:1567-74. 2003
    ..It was previously demonstrated that the CMV decamer (10-mer) peptide pp65(341-350), QYDPVAALFF, was able to induce CMV-specific CTLs in HLA-A*2402 CMV-seropositive individuals...
  3. pmc Ex vivo screening for immunodominant viral epitopes by quantitative real time polymerase chain reaction (qRT-PCR)
    Maurizio Provenzano
    Molecular Immunology Section, Department of Transfusion Medicine, Clinical Center, NIH, Bethesda, USA
    J Transl Med 1:12. 2003
    ....
  4. ncbi request reprint Identification of immune dominant cytomegalovirus epitopes using quantitative real-time polymerase chain reactions to measure interferon-gamma production by peptide-stimulated peripheral blood mononuclear cells
    Maurizio Provenzano
    Department of Transfusion Medicine, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Immunother 25:342-51. 2002
    ..As a result, this method measures naturally induced immune reactions...
  5. pmc Functional heterogeneity of vaccine-induced CD8(+) T cells
    Vladia Monsurro
    Immunogenetics Section, Department of Transfusion Medicine, Clinical Center, and Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 168:5933-42. 2002
    ..In addition, CD45RA/CD27 expression may be more informative about the status of activation of circulating T cells than their status of differentiation...
  6. ncbi request reprint Proteasomal cleavage does not determine immunogenicity of gp100-derived peptides gp100 209-217 and gp100 209-217T210M
    Dirk Nagorsen
    Immunogenetics Section, Department of Transfusion Medicine, NIH Clinical Center, 10 Center Drive, Bethesda, MD 20892 1502, USA
    Cancer Immunol Immunother 53:817-24. 2004
    ..Since the final antigenic nonamer is not directly produced by the proteasome, additional further factors may influence the antigenic peptide availability, such as post-proteasomal processing and intracellular peptide transport...
  7. ncbi request reprint Gene expression signatures of interleukin-2 in vivo and in vitro and their relation to anticancer therapy
    Ping Jin
    Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA
    Crit Rev Immunol 27:437-48. 2007
    ..This information will not only lead to a better utilization of this biological agent in clinical practice but it may also provide important information about how immune-mediated tissue rejection occurs...
  8. pmc The antileukemia effect of HLA-matched NK and NK-T cells in chronic myelogenous leukemia involves NKG2D-target-cell interactions
    Giuseppe Sconocchia
    Stem Cell Allotransplantation Section, Hematology Branch, National Heart Lung and Blood Institute, Department of Transfusion Medicine, Clinical Center, National Institutes of Health NIH, Bethesda, MD 20892, USA
    Blood 106:3666-72. 2005
    ..However, in vivo, CML cells may avoid NK-cell-mediated immune destruction by immune escape, shedding MICA into the plasma, thereby down-regulating NKG2D on CML CD56(+) cells...
  9. doi request reprint Pilot study of mutant ras peptide-based vaccine as an adjuvant treatment in pancreatic and colorectal cancers
    Antoun Toubaji
    Cancer Vaccine Section, Vaccine Branch, NCI, NIH, NNMC, Bldg 8, Room 5101, 8901 Wisconsin Ave, Bethesda, MD 20889, USA
    Cancer Immunol Immunother 57:1413-20. 2008
    ..In this phase II clinical trial, we aimed to test the feasibility of using a specific mutant ras peptide vaccine as an adjuvant immunotherapy in pancreatic and colorectal cancer patients...
  10. ncbi request reprint Identification of HLA-A33-restricted CMV pp65 epitopes as common targets for CD8(+) CMV-specific cytotoxic T lymphocytes
    Jong Baeck Lim
    Department of Laboratory Medicine, Yonsei University College of Medicine, Seoul, Korea
    Exp Hematol 34:296-307. 2006
    ..To identify an immunodominant HLA-A33-restricted epitope within the CMV matrix phosphoprotein 65 (pp65) that could be used to elicit CMV-specific CTLs...
  11. ncbi request reprint Adoptive immunotherapy for cytomegalovirus (CMV) disease in immunocompromised patients
    Jong Baeck Lim
    Department of Laboratory Medicine, Yonsei University College of Medicine, Seoul, Korea
    Yonsei Med J 45:18-22. 2004
    ....
  12. ncbi request reprint Comprehensive epitope mapping of the Epstein-Barr virus latent membrane protein-2 in normal, non tumor-bearing individuals
    Maurizio Provenzano
    Immune Oncology Section, Department of Surgery, University Hospital ZLF, Hebelstrasse 20, 4031 Basel, Switzerland
    Cancer Immunol Immunother 56:1047-63. 2007
    ..We believe that the usefulness of these epitopes occurring naturally in non-cancer bearing patients as reagents for the immunization of patients with early or advanced stage NPC deserves further evaluation...
  13. ncbi request reprint Use of quantitative real-time PCR to determine immune cell density and cytokine gene profile in the tumor microenvironment
    Simone Mocellin
    Surgery Branch, Department of Oncological and Surgical Sciences, University of Padova, Padova, Italy
    J Immunol Methods 280:1-11. 2003
    ..The molecular mechanisms underlying tumor responsiveness to immunotherapeutic manipulations remain elusive. Investigators are therefore searching for new technologies to study immune-related events occurring in the tumor microenvironment...